Dual-Platform ABCD1 mRNA Therapy for X-Linked ALD | Method2Model
Most ALD mRNA programs don’t fail on biology—they fail on decision ambiguity: unclear success definitions, CNS “signal” without thresholds, and CMC variability that quietly changes what a “dose” means. In this case study, Method2Model turns a dual-platform ABCD1 mRNA concept (LNP + EV, Peripheral-First → CNS) into a stage-locked decision engine: a full A–G architecture, a formal formula pack, and an executable Stage-3 core (mouse branch) with verification evidence. The result is decision-grade Go/No-Go/Pivot governance—so teams can move faster with fewer reruns, fewer false conclusions, and fewer late-stage surprises.
